Synaptic Systems

Rudolf-Wissell-Str. 28
37079 Göttingen, Germany
Phone: +49 551-50556-0
Fax: +49 551-50556-384
E-mail: sales@sysy.com
Web: www.sysy.com

Abeta-pE3

Cat.No. 218 311; Monoclonal mouse antibody, 100 µg purified IgG (lyophilized)

Data Sheet

Reconstitution/ Storage	100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H_2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use.
Applications	**WB**: 1 : 1000 (see remarks) **IP**: yes **ICC**: not tested yet **IHC**: 1 : 100 (see remarks) **IHC-P/FFPE**: 1 : 1000 up to 1 : 5000
Clone	1-57
Subtype	IgG2b (κ light chain)
Immunogen	Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Epitop	Epitop: AA 3 to 5 from human Abeta-pE3 (UniProt Id: P05067)
Reactivity	Reacts with: human (P05067), rat (P08592), mouse (P12023). Other species not tested yet.
Specificity	Specific for Abeta-pE3.
Remarks	**WB**: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested. Boil membrane after blotting for 3min. **IHC**: recommended protocol

TO BE USED IN VITRO / FOR RESEARCH ONLY
NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the **a**myloid **beta**-peptides (**Abeta**, **Aβ**) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and **p**yro**glu**tamyl (**pGlu**)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; **Abeta-pE3** and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.

Selected References SYSY Antibodies

N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.
Antonios G, Saiepour N, Bouter Y, Richard BC, Paetau A, Verkkoniemi-Ahola A, Lannfelt L, Ingelsson M, Kovacs GG, Pillot T, Wirths O, et al.
Acta neuropathologica communications (2013) 1: 56. **IHC, WB; tested species: human**

The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease.
Murray CE, Gami-Patel P, Gkanatsiou E, Brinkmalm G, Portelius E, Wirths O, Heywood W, Blennow K, Ghiso J, Holton JL, Mills K, et al.
Acta neuropathologica communications (2018) 6(1): 62. **IHC-P; tested species: human**

Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA
The Journal of biological chemistry (2012) 287(11): 8154-62. **IP**

Selected General References

Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.
Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, Shia MA, Fine RE
Neuroscience letters (2011) 505(2): 109-12.

Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.
Perez-Garmendia R, Ibarra-Bracamontes V, Vasilevko V, Luna-Muñoz J, Mena R, Govezensky T, Acero G, Manoutcharian K, Cribbs DH, Gevorkian G
Journal of neuroimmunology (2010) 229(1-2): 248-55.

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, et al.
Nature medicine (2008) 14(10): 1106-11.

Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.
Hook V, Schechter I, Demuth HU, Hook G
Biological chemistry (2008) 389(8): 993-1006.

Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.
Böhme L, Hoffmann T, Manhart S, Wolf R, Demuth HU
Biological chemistry (2008) 389(8): 1055-66.

Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, von Hörsten S, et al.
Journal of neurochemistry (2008) 106(3): 1225-36.

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.
Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, et al.
The Journal of biological chemistry (2001) 276(46): 42645-57.

Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta.
Wood SJ, Maleeff B, Hart T, Wetzel R
Journal of molecular biology (1996) 256(5): 870-7.

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.
Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE
The Journal of biological chemistry (1996) 271(8): 4077-81.